DIA

Oligonucleotide-Based Therapeutics Conference

SEPTEMBER 23-25, 2026 | ARLINGTON, VA

CALL FOR ABSTRACTS

ABSTRACT SUBMISSION DETAILS AND GUIDELINES
SUBMISSION DEADLINE: JANUARY 14, 2026

Are you a professional involved in oligonucleotide-based therapeutics? If so, DIA wants to hear from YOU! The DIA *Oligonucleotide-Based Therapeutics Conference* brings together leading experts to inform, educate, and share advancements in oligonucleotide-based therapeutic product development.

To ensure that we have the most comprehensive and cutting-edge program, we are seeking abstract submissions from professionals like yourself, who are pushing the boundaries in their respective fields. We encourage you to **submit abstracts** that reflect the latest trends, innovations, and best practices in oligonucleotide-based therapeutics. We will be accepting the following formats:

- **Presentations:** 15-20-minute presentation to be bundled with other presentations to create a session (1 author/speaker)
- **Sessions:** 60-75-minute total session (1 author/speaker + 2 additional speakers)
- **Workshop:** 60-75-minute workshop delivered in an interactive/simulation or role-playing format (1 author/speaker + 2 additional speakers)

The Oligo Program Committee is seeking abstracts on the following topics (keep in mind, business use cases and lessons learned are encouraged in all topic areas). Please note that topics in addition to those listed below, that you feel are relevant, may be submitted for evaluation and possible selection.

Clinical Track

With over a dozen approved oligonucleotide-based therapeutics and nearly 100 more in clinical testing, this track will explore lessons learned and the evolving challenges in clinical development and application.

- How protein products of target genes can be used for dose selection and surrogate endpoints
- Strategies for combination use of oligonucleotides
- Approaches to special populations (e.g., pediatric, geriatric, hepatic, renal impairment)
- Clinical assessment of oligonucleotide metabolites (peptides, small molecules)
- Extra-hepatic updates: CNS, ocular, and muscle
- Extra-hepatic updates: kidney, adipose, and lung
- Tackling organs with multiple cell types when tissue specificity isn't enough
- Large clinical trials of oligonucleotides: Lessons learned and a look ahead
- Reversal agents: When and how to develop them
- Safety: Translating preclinical assessments (in silico, in vivo) to human trials—*is what you see what you get?*
- Safety: Insights from Phase 3 and postmarketing experience
- Safety: Managing mechanistic risks of genetically targeted oligonucleotides (e.g., thrombocytopenia, proteinuria, CSF parameters, LFTs)
- Comparing regulatory experiences in first-in-human trials across regions (U.S., EU, Asia)
- Case studies of approved oligonucleotides—how past challenges enable future opportunities

Non-Clinical Track

This track will focus on nonclinical development and safety assessments, exploring the science and strategy driving oligonucleotide innovation.

- CNS delivery (IT, systemic administration, BBB transit, cell-type targeting, safety, study design)
- Extra-hepatic (non-CNS) delivery and safety considerations
- ICH S13 and evolving guidance
- Delivery technologies—current and next-generation
- Impurities/stereoisomers: when do they become a safety concern?
- Long half-life compounds and use of antidotes
- N-of-1/few and platform-based approaches
- New approach methodologies (NAMs)
- Oligonucleotide therapeutics for RNA activation and target gene upregulation
- Nonclassical chemistries
- Safety and toxicology best practices
- Streamlining nonclinical safety endpoints
- Use of animal-active surrogates

CMC Track

This track provides an interactive forum for innovators and regulators to exchange perspectives on the cutting edge of oligonucleotide CMC. Attendees will gain actionable insights into emerging policies, evolving global guidance, and strategies for navigating this complex and rapidly advancing space.

- Alternative synthesis methods
- Clinical and commercial product case studies
- CMC aspects of oligonucleotide delivery
- CMC considerations for longmers
- Comparability approaches
- Novel oligonucleotide therapeutic considerations
- Emerging CMC policies
- Generics and comparability (stereochemistry focus)
- ICH aspects, including Q6 and S13
- Sustainable oligonucleotide manufacturing
- Global regulatory guidance and harmonization
- mRNA therapeutics
- New China oligonucleotide guidance
- Novel stability approaches
- Platform approaches
- Process modeling for oligonucleotides
- Regulatory aspects of API synthesis and site transfers

Submit Your Abstract at DIAglobal.org/Abstracts

CALL FOR PRESENTATION ABSTRACTS

SUBMISSION DEADLINE: January 14, 2026

GENERAL SUBMISSION REQUIREMENTS

- All submissions must be submitted online
- For complete submission requirements and to submit your abstract go to DIAglobal.org/Abstracts

SUBMISSION TIPS

- Ideal submissions will contain practical content and shared experiences
- Theoretical topics and content is acceptable, however, it should be supported with proof of concepts and use cases
- Diverse topics and sessions are welcomed and encouraged within the scope of the forum
- Please select the interest area that best fits with your proposal. If your topic is relevant to more than one interest area, please indicate that in your abstract summary.
- Abstracts should be written using clear language and descriptions to provide enough clarity for the selection committee to review and understand

REQUIRED DOCUMENTATION FOR ALL ABSTRACTS

- Participant Disclosure Information: All abstract authors must disclose any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he or she must complete and submit a Participant Disclosure in order to participate in the program
- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted abstracts will be available on DIA's website for attendee download.

SUBMISSION GUIDELINES

Submitting a PRESENTATION ABSTRACT (All abstracts must be submitted online)

15-20-minute presentation, bundled with other presentations to create a session. Abstract author is considered the presenter (co-presenters are not permitted) and will be responsible for:

- Adhering to the program development guidelines and timelines
- Working with chair and other presenters in creating a balanced program offering
- Preparing and delivering a PowerPoint presentation

Submitting a SESSION ABSTRACT (All abstracts must be submitted online)

60-75-minute total session. Abstract author will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting speakers and ensuring good representation/diversity in their selection. Maximum of 3 speakers per session (including author) and 1 speaker per company
- Working with the Session Chair to communicate with speakers regarding their role in the session

Submitting a SHORT COURSE ABSTRACT (All abstracts must be submitted online)

Three-hour, interactive presentation delivered in small group format. Abstract author is considered the Short Course Lead Instructor and will be responsible for:

- Adhering to the program development guidelines and timelines
- Recruiting co-instructors and ensuring good representation/diversity in their selection. (3 speaker max, must all be from different companies)
- Communicating with co-instructors regarding their role in the short course and reviewing presentation materials (note: PowerPoint presentations are required from each instructor)
- Managing the short course, including the facilitation of audience questions and interactions

Abstract Submission Deadline: January 14, 2026

Notification: Week of March 9, 2026

Final PowerPoint Presentations Due: September 2, 2026

Please submit all abstracts online at: DIAglobal.org/Abstracts

Questions: Contact Jessica L. Roman, MS, CMP, Associate Director, Specialty Meetings at Jessica.Roman@DIAglobal.org

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. **Do not wait until the last day.**

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Author Information

Abstract Information

Track: Select either Clinical, Non-Clinical, or CMC

Interest Area: Choose from the drop down

Keywords: Provide one or more keywords to highlight your abstract.

Examples of keywords: Personalized Medicine, Health Technology Assessment, etc. (100 characters)

Level of Difficulty: Beginner, Intermediate, or Advanced

Learning Objectives: Provide 2-3 learning objectives that clearly explain what participants should be able to do after attending this event. For a list of suggested verbs to create these objectives, click here. (400 Characters)

Overview: Please provide 2-3 sentences summarizing your abstract. This summary will be used as the overview description in the DIA program for marketing purposes (250 Characters including spaces)

Abstract Details: Please provide complete details about your abstract. Information such as scientific, technical, process issues, design/methods, results/outcomes, case studies, statistics, key findings, etc., that would support your proposal should be included here. This information will be used by the Program Committee to learn more about the purpose of your abstract. Is there an interactive component to your topic? If so, please indicate in the abstract details how you would be able to include an interactive learning experience for attendees. (2000 Characters including spaces)

Submit Your Abstract at DIAglobal.org/Abstracts